A milestone payment of 200 million yen is scheduled to be received under the license agreement with Hisamitsu Pharmaceutical. The payment is triggered by the start of a Phase II clinical trial and will be recorded as operating revenue in Q4 of the fiscal year ending December 2026. The impact has already been factored into the earnings forecast and no additional earnings revision is planned at this time.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4579","jir_company_name":"RaQualia Pharma Inc.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-10-21","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/10\/4579-20261021-01.pdf","jir_short_summary":"A milestone payment of 200 million yen is scheduled to be received under the license agreement with Hisamitsu Pharmaceutical. The payment is triggered by the start of a Phase II clinical trial and will be recorded as operating revenue in Q4 of the fiscal year ending December 2026. The impact has already been factored into the earnings forecast and no additional earnings revision is planned at this time.","jir_summary":"### Key Points\nRaQualia Pharma Inc. announced that, following the start of a Phase II clinical trial for a transdermal product containing a novel sodium channel blocker licensed to Hisamitsu Pharmaceutical, it expects to receive a milestone payment of 200 million yen. This milestone will be recognized as operating revenue in Q4 of the fiscal year ending December 2026, and its effect on consolidated results has already been incorporated.\n\n### Business Impact and Outlook\nNo additional earnings revisions are planned at this time. Through strengthened collaboration with Hisamitsu Pharmaceutical, the company aims to enhance corporate value by providing treatment options in the pain-related field. Depending on clinical development progress, this may affect future development and commercialization prospects and associated revenues.","jir_financial_highlights":"Milestone payment: 200 million yen (Scheduled recognition)","jir_category":"","jir_hashtags":"#RaQualiaPharma, #MilestonePaymentForDrugDevelopment, #ClinicalTrialProgress","jir_key_figures":"Milestone payment: 200 million yen\nRecognition timing: Q4 of the fiscal year ending December 2026\nClinical progress: Start of Phase II clinical trial (related to agreement with Hisamitsu Pharmaceutical)","jir_meta_title":"RaQualia Pharma Inc. \u2014 Notice of Milestone Payment Following Start of Phase II Clinical Trial for a Novel Sodium Channel Blocker\uff5c2026-10","jir_meta_description":"RaQualia Pharma Inc. expects to receive a 200 million yen milestone payment under its license agreement with Hisamitsu Pharmaceutical. Details on the impact of the Phase II clinical trial start and planned recognition in Q4 of the fiscal year ending December 2026.","jir_og_title":"RaQualia Pharma Inc. \u2014 Scheduled Receipt of 200 million yen Milestone Payment for Novel Sodium Channel Blocker","jir_og_description":"A 200 million yen milestone payment under the agreement with Hisamitsu Pharmaceutical is expected to be recognized in Q4 of the fiscal year ending December 2026. Overview of clinical progress and outlook.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":57587,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"earnings_guidance","footnotes":""},"sector":[],"importance":[],"class_list":["post-133127","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n